Timing of Flu Vaccine in HIV Patients May Affect Incidence Later in Season
Early season influenza vaccination of patients with HIV may influence the risk of infection later in the season.
Early season influenza vaccination of patients with HIV may influence the risk of infection later in the season.
High-dose inactivated influenza vaccine (IIV-HD) demonstrates significantly improved immunogenicity compared to standard-dose inactivated influenza vaccine (IIV-SD) in older adults.
Substantial proportions of children who received the MenACWY-CRM conjugate vaccine between the ages of 2 and 10 years continued to have persistent antibodies against all four serogroups, with robust increases in antibody titers after a booster dose 5 years following the primary vaccination series
Concomitant administration of a licensed quadrivalent human papillomavirus (HPV4) vaccine and bivalent rLP2086, an investigational Neisseria meningitidis serogroup B (MnB) vaccine, generated robust immune responses to both vaccines in healthy adolescents.
The safety and immunogenicity of the investigational combination vaccine, DTaP5-IPV-Hib-HepB, when given as a 3-dose infant series, were comparable to equivalent licensed component vaccines.
Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) in the prevention of vaccine-type community-acquired pneumonia (VT-CAP) or invasive pneumococcal disease (VT-IPD) declined with age.
Two investigational formulations of meningococcal MenABCWY vaccines have shown comparable immunogenicity to the licensed vaccines (MenACWY-CRM) and serogroup B (4CMenB), and the full outer membrane vesicle formulation gave higher GMT responses against B test strains.
Revaccination of children with live-attenuated influenza vaccine (LAIV) over 2 consecutive seasons did not reduce vaccine efficacy, and was similar to, or higher than, efficacy of a single LAIV administration in the second season.
The investigational Intradermal (ID) Quadrivalent Inactivated Influenza Vaccine (IIV4-ID) tested in a Phase 3 clinical trial during the 2012-13 influenza season produced antibody responses to B strains that were superior to a licensed split-virion trivalent influenza vaccine (IIV3-ID) containing the alternate strain, and noninferior for the A and matched B strains.
PCV13, a 13-valent pneumococcal conjugate vaccine, had an efficacy rate of 45.56% for preventing the first episode of vaccine-type pneumococcal community-acquired pneumonia (VT-CAP) in healthy adults 65 years of age and older.
Please login or register first to view this content.